Innocan Pharma paves its way to LPT-CBD CMC key milestones for FDA approval
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million
Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue
Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the company's latest groundbreaking findings. Research over the past several months has identified animals that metabolize cannabidiol (CBD), administered as a liposomal CBD injection, in a manner similar to humans. This means that results related to LPT-CBD metabolism obtained from experiments with these types of animals are likely to be very applicable to humans. The company expects that this development could improve the strength of its application to the FDA for new drug approval.